Cancer
Malignant Liver Neoplasm
CI-CAN-00003177Explore in graph →
Top-level908 active trials14 approved drugs17 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer
CI-CAN-00003177Explore in graph →
Clinical trials
4,123 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (459)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07413354 | Tislelizumab Combined With Huaier Granule as First-line Treatment for Unresectable Hepatocellular Carcinoma | recruiting | Phase 2 | 94 | Tongji HospitalOTHER | 1 | May 12, 2026 | clinicaltrials |
| NCT06852820 | 68Ga-PSMA-11 PET-directed Radioligand Therapy in Metastatic Hepatocellular Carcinoma (HCC) | recruiting | Phase 2 | 10 | Melissa LumishOTHER | 1 | May 8, 2026 | clinicaltrials |
| Sorafenib Plus Doxorubicin in Patients With Advanced Hepatocellular Carcinoma With Disease Progression on Sorafenib |
| active not recruiting |
| Phase 2 |
| 30 |
| Memorial Sloan Kettering Cancer CenterOTHER |
| 1 |
| May 6, 2026 |
| clinicaltrials |
| NCT05027425 | Durvalumab (MEDI4736) and Tremelimumab for Hepatocellular Carcinoma in Patients Listed for a Liver Transplant | terminated | Phase 2 | 8 | University of CincinnatiOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT06239194 | Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 285 | ModeX Therapeutics, An OPKO Health CompanyINDUSTRY | 1 | May 6, 2026 | clinicaltrials |
| NCT07570849 | Chidamide Combined With Chemotherapy and Immunotherapy as First-line Treatment for Advanced Intrahepatic Cholangiocarcinoma | recruiting | Phase 2 | 35 | Shanghai Zhongshan HospitalOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT03107416 | Delivering a Diuretic Into the Liver Artery Followed by Plugging up the Artery to Starve Out Liver Cancer Cells | active not recruiting | Phase 1 / Phase 2 | 30 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT07014150 | Neoadjuvant Therapy of Iparomlimab and Tuvonralimab Combined With Lenvatinib for Hepatocellular Carcinoma | recruiting | Phase 2 | 33 | Peking Union Medical College HospitalOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT07122089 | Evaluation of SIRT Followed by Immunotherapy for Treatment of Hepatocellular Carcinoma With Portal Vein Thrombosis(IOSPHERE) | recruiting | Phase 2 | 80 | Center Eugene MarquisOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT07226063 | Maintenance Zanzalintinib and Durvalumab in Participants With Advanced Hepatocellular Cancer | not yet recruiting | Phase 2 | 16 | Amit MahipalOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT03482102 | Durvalumab (MEDI4736) and Tremelimumab and Radiation Therapy in Hepatocellular Carcinoma and Biliary Tract Cancer | active not recruiting | Phase 2 | 37 | Massachusetts General HospitalOTHER | 1 | May 4, 2026 | clinicaltrials |
| NCT07565415 | Nanocrystalline Megestrol Acetate Versus Placebo for Anorexia in Patients With Unresectable Hepatocellular Carcinoma Receiving TACE Combined With Targeted and Immunotherapy | not yet recruiting | Phase 2 | 88 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | May 4, 2026 | clinicaltrials |
| NCT04118114 | Phase II Study of PRL3-ZUMAB in Advanced Solid Tumors | completed | Phase 2 | 14 | National Cancer Centre, SingaporeOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT07560488 | Ipilimumab N01 Combined With Sintilimab, Bevacizumab Biosimilar, and Hepatic Arterial Infusion Chemotherapy as Conversion Therapy for Unresectable Intermediate-Advanced Hepatocellular Carcinoma | recruiting | Phase 2 | 43 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT07560566 | SHIELD: Sorafenib Hand-foot Syndrome Inhibition With Pre-Emptive Local Delivery of Topical Indomethacin | recruiting | Phase 2 | 39 | National Taiwan University HospitalOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT07138885 | A Phase II, Single-Arm, Prospective Trial on the Efficacy and Safety of QL1706 Combination Regimen as Second-Line Therapy for Targeted-Immunotherapy-Resistant Hepatocellular Carcinoma(DRIVE-II) | active not recruiting | Phase 2 | 62 | Sun Yat-sen UniversityOTHER | 1 | Apr 29, 2026 | clinicaltrials |
| NCT07274774 | SBRT Plus Systemic Therapy vs Systemic Therapy Alone in BCLC C Hepatocellular Carcinoma | recruiting | Phase 2 | 184 | Shandong Cancer Hospital and InstituteOTHER | 1 | Apr 28, 2026 | clinicaltrials |
| NCT07543783 | Efficacy and Safety of Low-dose Bevacizumab Plus Adebrelimab Combined With Transarterial Chemoembolization Followed by Hepatic Arterial Infusion Chemotherapy (TACE-HAIC) as First-line Treatment for Unresectable Hepatocellular Carcinoma: A Single-arm Phase 2 Trial | not yet recruiting | Phase 2 | 38 | Third Affiliated Hospital, Sun Yat-Sen UniversityOTHER | 0 | Apr 28, 2026 | clinicaltrials |
| NCT05440708 | A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma | recruiting | Phase 1 / Phase 2 | 193 | Tvardi Therapeutics, IncorporatedINDUSTRY | 1 | Apr 27, 2026 | clinicaltrials |
| NCT05103904 | Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant | terminated | Phase 2 | 3 | Emory UniversityOTHER | 1 | Apr 24, 2026 | clinicaltrials |
| NCT06045975 | Durvalumab/Tremelimumab in Neoadjuvant and Adjuvant Setting in Patients With HCC Treated by by Percutaneous Ablation Procedure(DUMELEP) | active not recruiting | Phase 2 | 30 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Apr 24, 2026 | clinicaltrials |
| NCT07175441 | Evaluation of RBS2418 in Combination With Tremelimumab Plus Durvalumab in Participants With Advanced Unresectable Hepatocellular Carcinoma | recruiting | Phase 2 | 220 | Riboscience, LLC.INDUSTRY | 1 | Apr 24, 2026 | clinicaltrials |
| NCT07422753 | A Prospective, Randomized Study of TACE Combined With Sintilimab, Bevacizumab, and Ipilimumab N01 Treating Advanced HCC | recruiting | Phase 2 | 36 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Apr 24, 2026 | clinicaltrials |
| NCT05625893 | Proton Beam Radiotherapy Followed by Tecentriq and Avastin for Primary Liver Cancer With Vp2-4 Portal Vein Invasion | completed | Phase 2 | 63 | Samsung Medical CenterOTHER | 1 | Apr 23, 2026 | clinicaltrials |
| NCT05655949 | Y-90 With Durvalumab/Gem/Cis in Intrahepatic Cholangio | recruiting | Phase 2 | 30 | Beth Israel Deaconess Medical CenterOTHER | 1 | Apr 22, 2026 | clinicaltrials |
| NCT03213678 | Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial) | completed | Phase 2 | 18 | National Cancer Institute (NCI)NIH | 2 | Apr 21, 2026 | clinicaltrials |
| NCT06860490 | HAIC Combined With Sintilimab Plus Bevacizumab Biosimilar for Advanced Hepatocellular Carcinoma (TASK-03) | recruiting | Phase 2 | 164 | Fudan UniversityOTHER | 1 | Apr 21, 2026 | clinicaltrials |
| NCT02174549 | Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer | recruiting | Phase 1 / Phase 2 | 25 | Teclison Ltd.INDUSTRY | 1 | Apr 20, 2026 | clinicaltrials |
| NCT05969860 | At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer | recruiting | Phase 2 | 220 | Mayo ClinicOTHER | 1 | Apr 20, 2026 | clinicaltrials |
| NCT06233981 | Phase II Study of Moderate-dose Hypofractionated RT Combined With Tislelizumab for HCC With Diffuse Tumor Thrombosis | completed | Phase 2 | 30 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Apr 17, 2026 | clinicaltrials |
| NCT06777316 | A Study of an FGFR2/3 Inhibitor (CGT4859) in Patients With Cholangiocarcinoma and Other Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 110 | Cogent Biosciences, Inc.INDUSTRY | 2 | Apr 17, 2026 | clinicaltrials |
| NCT07537777 | Benmelstobart Plus Anlotinib Combined With SBRT for Patients With Hepatocellular Carcinoma Failing First-Line Targeted Therapy | not yet recruiting | Phase 2 | 29 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Apr 17, 2026 | clinicaltrials |
| NCT07537972 | Denosumab Strategy for Liver Cancer With Bone Metastases | not yet recruiting | Phase 2 | 50 | Tongji HospitalOTHER | 1 | Apr 17, 2026 | clinicaltrials |
| NCT03259867 | Combination of TATE and PD-1 Inhibitor in Liver Cancer(TATE-PD1) | recruiting | Phase 2 | 54 | Teclison Ltd.INDUSTRY | 1 | Apr 16, 2026 | clinicaltrials |
| NCT05842174 | Targeting Ischemia-Induced Autophagy Dependence in Hepatocellular Carcinoma(TAQE) | recruiting | Phase 1 / Phase 2 | 93 | VA Office of Research and DevelopmentFED | 1 | Apr 16, 2026 | clinicaltrials |
| NCT07223424 | Patient Preference for Subcutaneous vs. Intravenous Immune Therapy(PSI-Immune) | recruiting | Phase 2 | 880 | Diwakar DavarOTHER | 1 | Apr 16, 2026 | clinicaltrials |
| NCT07490262 | A Study to Evaluate the Efficacy and Safety of IBI310 and Sintilimab Combination Therapy in Patients With Hepatocellular Carcinoma as First-line Treatment. | recruiting | Phase 2 / Phase 3 | 680 | Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.INDUSTRY | 1 | Apr 16, 2026 | clinicaltrials |
| NCT06638931 | Agnostic Therapy in Rare Solid Tumors(ANTARES) | recruiting | Phase 2 | 28 | Instituto do Cancer do Estado de São PauloOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT03213665 | Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial) | completed | Phase 2 | 20 | National Cancer Institute (NCI)NIH | 2 | Apr 13, 2026 | clinicaltrials |
| NCT05257590 | CVM-1118 in Combination With Nivolumab for Unresectable Advanced Hepatocellular Carcinoma | recruiting | Phase 2 | 95 | TaiRx, Inc.INDUSTRY | 1 | Apr 13, 2026 | clinicaltrials |
| NCT06362369 | A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy | recruiting | Phase 1 / Phase 2 | 126 | 7 Hills Pharma, LLCINDUSTRY | 1 | Apr 13, 2026 | clinicaltrials |
| NCT07522411 | Sequential FOLFOX-HAIC-TACE Plus Sintilimab-Bevacizumab Neoadjuvant Therapy Versus Direct Resection in Resectable High-Risk Recurrence Hepatocellular Carcinoma | not yet recruiting | Phase 1 / Phase 2 | 100 | BinYong LiangOTHER | 0 | Apr 13, 2026 | clinicaltrials |
| NCT07293468 | Comparison of SBRT and SIRT With Combination IO for Locally-advanced, Unresectable HCCs (BIIRTH)(BIIRTH) | recruiting | Phase 2 / Phase 3 | 106 | Tuen Mun HospitalOTHER_GOV | 1 | Apr 9, 2026 | clinicaltrials |
| NCT07518706 | Neoadjuvant Tislelizumab-Lenvatinib vs Surgery Alone in Stage Ia HCC With Narrow Margin | not yet recruiting | Phase 2 | 60 | Tianjin Medical University Cancer Institute and HospitalOTHER | 0 | Apr 9, 2026 | clinicaltrials |
| NCT04834674 | DEB-TACE Combined With Apatinib and PD-1 for the Treatment of Intrahepatic Cholangiocarcinoma | completed | Phase 2 | 20 | Sichuan Cancer Hospital and Research InstituteOTHER | 1 | Apr 7, 2026 | clinicaltrials |
| NCT07514429 | Regorafenib After Failure of Lenvatinib in Patients With Unresectable HCC: The RELEVANT-HCC Trial(RELEVANT-HCC) | not yet recruiting | Phase 2 | 24 | Ju Hyun ShimOTHER | 1 | Apr 7, 2026 | clinicaltrials |
| NCT07514455 | Regorafenib After Treatment Failure of First Line Immune Checkpoint Inhibitor Treatment in Advanced Hepatocellular Carcinoma Patients(RECOMEND) | not yet recruiting | Phase 2 | 20 | Ju Hyun ShimOTHER | 1 | Apr 7, 2026 | clinicaltrials |
| NCT07515469 | A Prospective, Single-Arm, Exploratory Study of the Safety and Efficacy of Neoadjuvant Treatment With QL1706, an Anti-PD-1/Anti-CTLA-4 Bispecific Antibody, in Resectable Stage IB and IIA Hepatocellular Carcinoma With High Recurrence Risk | not yet recruiting | Phase 2 | 30 | Tianjin Medical University Cancer Institute and HospitalOTHER | 0 | Apr 7, 2026 | clinicaltrials |
| NCT03916627 | Neoadjuvant Cemiplimab for the Treatment of Resectable NSCLC, HCC, and HNSCC in Adult Patients | active not recruiting | Phase 2 | 65 | Regeneron PharmaceuticalsINDUSTRY | 1 | Apr 6, 2026 | clinicaltrials |
| NCT07511504 | Y-90 Radioembolization, Durvalumab, Tremelimumab, and Zanzalintinib for the Treatment of Unresectable and Locally-Advanced Hepatocellular Carcinoma | not yet recruiting | Phase 2 | 40 | OHSU Knight Cancer InstituteOTHER | 1 | Apr 6, 2026 | clinicaltrials |
Data updated 22 days agoSource updated May 12, 2026source: clinicaltrials